These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 35790603)
1. Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Case-Control Study from The Netherlands, Italy and Germany. Holthuis E; Smits E; Spentzouris G; Beier D; Enders D; Gini R; Bartolini C; Mazzaglia G; Penning-van Beest F; Herings R Drugs Real World Outcomes; 2022 Dec; 9(4):597-607. PubMed ID: 35790603 [TBL] [Abstract][Full Text] [Related]
2. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Smits E; Andreotti F; Houben E; Crijns HJGM; Haas S; Spentzouris G; Schink T; Gini R; Bartolini C; Penning-van Beest F; Herings R Drugs Real World Outcomes; 2022 Jun; 9(2):199-209. PubMed ID: 34993898 [TBL] [Abstract][Full Text] [Related]
3. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study. Toorop MMA; Chen Q; Tichelaar VYIG; Cannegieter SC; Lijfering WM Eur Heart J; 2021 Oct; 42(40):4126-4137. PubMed ID: 34269375 [TBL] [Abstract][Full Text] [Related]
4. Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes. Arbel A; Abu-Ful Z; Preis M; Cohen S; Saliba W J Arrhythm; 2022 Feb; 38(1):67-76. PubMed ID: 35222752 [TBL] [Abstract][Full Text] [Related]
5. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1027-1036. PubMed ID: 33822401 [TBL] [Abstract][Full Text] [Related]
6. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation. Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323 [TBL] [Abstract][Full Text] [Related]
7. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Perreault S; de Denus S; White-Guay B; Côté R; Schnitzer ME; Dubé MP; Dorais M; Tardif JC Pharmacotherapy; 2020 Jan; 40(1):40-54. PubMed ID: 31758592 [TBL] [Abstract][Full Text] [Related]
8. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102 [TBL] [Abstract][Full Text] [Related]
9. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493 [TBL] [Abstract][Full Text] [Related]
10. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol. Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738 [TBL] [Abstract][Full Text] [Related]
11. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Komen JJ; Heerdink ER; Klungel OH; Mantel-Teeuwisse AK; Forslund T; Wettermark B; Hjemdahl P Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f72-f80. PubMed ID: 32324233 [TBL] [Abstract][Full Text] [Related]
12. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K; Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811 [TBL] [Abstract][Full Text] [Related]
13. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B Europace; 2020 Apr; 22(4):547-557. PubMed ID: 31598651 [TBL] [Abstract][Full Text] [Related]
14. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Beyer-Westendorf J; Ehlken B; Evers T Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891 [TBL] [Abstract][Full Text] [Related]
15. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619 [TBL] [Abstract][Full Text] [Related]